System for administering one or more anesthetic agents and method for providing advice for administering anesthetic agents
The system addresses the challenge of balancing anesthetic effects by using a bio-signal monitor and control device for continuous monitoring and closed-loop control, ensuring safe and reliable anesthesia through precise drug administration.
Patent Information
- Application Number
- PCT/EP2026/063867
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Existing anesthesia methods lack reliable, continuous monitoring and control systems for balancing the effects of anesthetic agents, leading to potential patient awareness and increased postoperative complications due to inadequate dosing.
A system comprising a bio-signal monitor, infusion pumps, and a control device that computes and displays indices related to anesthetic effects, allowing for closed-loop control and real-time adjustment of drug administration based on EEG-derived indices and pharmacokinetic-pharmacodynamic models.
Enables safe and reliable anesthesia by providing real-time feedback and precise control of anesthetic depth, reducing the risk of patient awareness and postoperative complications.
Smart Images

Figure EP2026063867_19112026_PF_FP_ABST
Abstract
Description
[0001] MT25044
[0002] Page 1
[0003] System for administering one or more anesthetic agents and method for providing advice for administering anesthetic agents
[0004] Description
[0005] The present disclosure relates to a system for administering one or more anesthetic agents and to a method for providing advice for administering anesthetic agents.
[0006] Balanced anesthesia is defined as a drug-induced state composed of three major effects on the patient: loss of consciousness (hypnosis), loss of pain sensation or response to noxious stimuli (analgesia) and loss of muscular activity (muscular relation, this latter effect being not always present or induced). In general anesthesia (GA), to obtain the desired effects, anesthesiologists can use different classes of drugs, mostly hypnotics and analgesics, and neuromuscular relaxants if an effect on muscular activity is needed, allowing patients to undergo surgery and other procedures without the distress and pain they would otherwise experience. The anesthesiologists generally must establish the proper amount of the anesthetic drug agents, for each patient and surgical context, in order to achieve - for each specific effect - a desired level, avoiding under-doses of agents, insufficient drug amount to reach the desired effect level, and over-doses, which are prone to lead to undesired and dangerous side effects.
[0007] The state of analgesia for surgery is reached by the administration of analgesics, wherein their demand is estimated for each patient and surgical context. Therefore, there is a need for continuous, preferably non-invasive monitoring of the analgesic effect in the patient. Nociception and the perception of pain define the need for analgesia to obtain pain relief. Automatic responses such as tachycardia, hypertension, emotional sweating and lacrimation, although non-specific, are regarded as signs of nociception and consequently inadequate analgesia.
[0008] Similarly to analgesics, when administering a sufficient dose of hypnotics, the resulting loss of consciousness ensures that the patient does not perceive stimuli consciously, but theMT25044
[0009] Page 2
[0010] neuro-vegetative and somatic responses are not necessarily abolished. When administering a sufficient dose of analgesics, nociception stimuli are blocked, and neuro-vegetative and somatic responses are prevented. However, analgesics do not necessarily result in a loss of consciousness and amnesia. In summary, analgesia and hypnosis are distinct components or effects of GA but they are not independent. Rather, there is a link between both, a link that also extends to the third effect, the muscular relaxation.
[0011] Anesthesia generally can be regarded as a dynamic process where the balanced effects of the anesthetic drugs are counteracted by the intensity of the different stimuli occurring during surgery. When an equilibrium resulting therefrom is broken, a patient could evolve to a different anesthetic depth, without the anesthesiologist being aware of it, resulting potentially in an intraoperative awareness of the patient. One of the objectives of modern anesthesia hence is to ensure adequate level of (un-)consciousness to prevent awareness without inadvertently overloading the patient with anesthetics (hypnotics and analgesics), which might cause increased postoperative complications.
[0012] There are several widely used clinical methods for assessing the level of consciousness during GA, including the Observer's Assessment of Alertness and Sedation scale (OAAS) and the Ramsey Sedation Scale. However, the disadvantages of using clinical scales in the operating room are that they cannot be used continuously and that they are cumbersome to perform. Furthermore, they require the patient's collaboration, which in some cases might be difficult. This has led to the investigation of an automated assessment of the level of consciousness.
[0013] In the last decades, some automatic devices have been introduced into the market to provide an objective quantification of a level of consciousness of the patient, relating to a hypnotic effect. The most prevailing monitoring technologies rely on the electroencephalogram (EEG) where the scalp bioactivity generated in the brain cortex is recorded and subsequently processed to extract distinct EEG features which feed a model or algorithm that maps EEG signal-extracted information into an index, typically in a range of 0 to 100, which it is highly correlated with the hypnotic drug concentration in the brain. EEG features belong either to the frequency domain or the time domain of the signal. The models used to map EEG features to the drug concentration range from simple polynomials to more complex functions such as neural networks, with their parameters estimated to give the best fitting.MT25044
[0014] Page 3
[0015] A nociception-effect-related measurement based on the EEG has been proposed by E. W. Jensen et al., “Monitoring hypnotic effect and nociception with two EEG-derived indices, qNOX and qCON, during general anesthesia”, Acta Anaesthesiologica Scandinavica, 2014; 58:933-941. Similarly to EEG-based hypnosis monitors, such an index combines a set of different extracted EEG features in a model (implemented either with a quadratic polynomial or with an Adaptive Neuro Fuzzy Inference System (ANFIS) neural network) that maps, under the best fitting, the EEG features summarized as an index, ranging between 0 and 100, with the probability of patient’s response to noxious stimuli.
[0016] A method for computing indices of consciousness and nociception is disclosed in WO 2017 / 012622 A1.
[0017] For safe surgical procedures it is crucial for the anesthesiologist to possess objective methods to estimate continuously the level of each GA component (unconsciousness, analgesia, and immobility) within different phases of the surgical procedure as well as to be able to control the administration of different drugs related with each component. Traditionally, for intravenous anesthesia, an anesthetic dose-response or dose-effect relationship is described under pharmacokinetics (PK) and pharmacodynamics (PD) models (PK-PD). While the PK part describes the drug pharmacokinetic behavior which is how the drug is distributed through different parts of the body, the drug concentration in the plasma (Cp) representing one the most relevant parameters, the PD part of the model deals with the end response or effect, produced at the biophase or the location where the drug acts. The pharmacodynamic behavior of the drug described by the PD model is decomposed into two parts, one describing the drug concentration at the biophase, named effect-site concentration (Ce), and the other describing the observed effect. For instance, for a hypnotic drug, such as propofol, the PK model part will describe the distribution of the drug in different parts of the body as a function of time, in particular, its plasma concentration, Cp. The PD part models the propofol concentration at the biophase (brain), resulting in an effect site concentration (Ce). Both Cp and Ce are variables in units of concentrations (mass / volume). In addition, the PD part maps the Ce with the observed effect of propofol, for instance, with the consciousness effect evaluated with the OAAS and the Ramsey Sedation Scale. The latter is mathematically modelled with a non-linear sigmoidal shape function, Hill model, between the Ce and a variable that is used to quantify the effect. Notably, some PK-PD models use EEG instead of clinical scales; thus, a PK-PD model based on EEG may be used.MT25044
[0018] Page 4
[0019] While effect measurements, e.g. based on the OAAS or Ramsey scale, are useful for clinical research and punctual estimation of a patient state, these are impractical for continuous state monitoring and drug titration. In that respect, traditionally the Ce concentration functions as a parameter are used to define a specific effect- related target. In this way, the anesthesia practitioner establishes an effect-site concentration (Ce) target for each GA component individually, depending on the surgical context, trying to reach each established target manually or using a target-controlled (TCI) infusion system, which calculates a dose profile scheme for that purpose. However, by defining an effect target by setting the effect-site concentration, from the patient's point of view the system behaves as an open-control system. However, since the introduction of monitoring systems, using indices derived from a patient's bio-signal information and hence providing measures directly related to the patient's state, the practitioners can redefine their desired effect target by setting a proper index target. The monitoring of different effect indices is the key to performing an optimized operation of the whole system (including infusion pumps and the patient).
[0020] The three basic components of GA (hypnosis or sedation, analgesia or nociception, and immobility or muscular relaxation) are typically not completely independent from each other but are influencing one another. An overlap between the basic components of GA is generally influenced by physiology as well as the surgical context, by a single or multiple different responses produced by a certain drug, and by the sum of multiple responses from combinations of drugs. For instance, analgesia may be more profound when an analgesic agent is combined with a hypnotic agent, and similarly a deeper hypnosis level may be reached when a hypnotic agent is administered together with an analgesic agent.
[0021] Different methods for monitoring nociception are known. For example, a monitoring method by skin conductance has been claimed in US 6,571,124 B1. In another example, US 7,024,234 B2 describes an algorithm that analyses a photoplethysmographic signal for the detection of an autonomic nervous system activity during sleep related breathing disorders. In yet another example, US 2005 / 143665 A1 describes a method for assessing a level of nociception during anesthesia by plethysmography from which a number of parameters are derived which are used to design a final index using a multiple logistic regression approach. In yet another example, US 6,685,649 B2 describes a method for detection of nociception by analysis of RR intervals achieved either from ECG data or blood pressure data. From the RR intervals an acceleration emphasized RR interval is defined. In yet another example, US 2009 / 0076339 A1 recites a method for monitoring the nociception of a patient during GA by extracting RR intervals from ECG and blood pressure. The method is basedMT25044
[0022] Page 5
[0023] on detection of simultaneous increase in HR and BP, defined as a non-baroreflex. In yet another example, EP 1 495715 A1 recites a method for measuring an index of hypnosis as well as index of analgesia which are independent from each other. Previous nociception methods do not rely on any EEG features. WO 2021 / 047912 A1 relates to a method for training a model usable to compute an index of nociception.
[0024] WO 2023 / 041552 A1 describes a system for administering different anesthetic agents, relating to different effects, to a patient within an anesthesia procedure which allows for a reliable, controlled anesthesia procedure while allowing to safely reach desired effects. The system comprises a bio-signal monitor for measuring at least one biological signal on the patient, an arrangement of infusion devices for infusing at least a first anesthetic agent and a second anesthetic agent to the patient, and a control device configured to compute, based on the at least one biological signal, a first index relating to a first effect caused by the first anesthetic agent and a second index relating to a second effect caused by the second anesthetic agent, wherein the control device is configured to compute, based on the first index and the second index, a first setting parameter for adjusting an infusion of the first anesthetic agent and a second setting parameter for adjusting an infusion of the second anesthetic agent.
[0025] As set forth above, anesthesia is a highly complex procedure that typically requires a high level of attention of the anesthesia practitioner. Particularly in intensive care, it is typically necessary to observe the relevant parameters and to quickly react if certain parameters are outside of a given range or if parameters do not evolve as they should.
[0026] It is an object to provide a system and method which allow for a safe and reliable anesthesia procedure.
[0027] This object is achieved by a system comprising the features of claim 1.
[0028] Accordingly, a system for administering one or more anesthetic agents to a patient comprises a bio-signal monitor, one or more infusion pumps, a screen and a control device. The bio-signal monitor is configured for measuring at least one biological signal of the patient. The system (e.g., the bio-signal monitor or the control device) is configured to compute, based on the at least one biological signal, one or more indices relating to one or more effects caused by the one or more anesthetic agents. The one or more infusion pumps for infusing one or more anesthetic agents ((e.g., one, two, three or even more infusion pumps for infusing one, two, three or more anesthetic agents and / or other drugs)MT25044
[0029] Page 6
[0030] to the patient in accordance with one or more setting parameters. The control device may be configured to concurrently display the one or more setting parameters and the one or more indices on the screen.
[0031] By providing these parameters and indices concurrently on the same display, the anesthesia practitioner is enabled to directly visually confirm the proper operation of the anesthesia, in particular, to confirm that the patient responds as expected under the infusion as reflected by the setting parameters. Similarly, the anesthesia practitioner is enabled to directly identify deviations from an intended response to the infusion due to the merging of the data. The time which the anesthesia practitioner needs to digest the data and realize its implications is strongly reduced not only because the data is visually close, but particularly because the anesthesia practitioner is enabled to discern a proper from potentially problematic anesthesia procedures upon first sight. As a result, the system allows for a safe and reliable anesthesia procedure.
[0032] The control device may be configured to concurrently display the one or more setting parameters and the one or more indices as time series on the screen. Therein, at least one of the one or more setting parameters and at least one of the one or more indices may be overlaid in a single diagram. This further improves the direct confirmation of a proper or problematic development of the procedure and much shorter reaction times of the anesthesia practitioner. The control device may be configured to control a target-controlled infusion (TCI).
[0033] The control device may be configured to compute the one or more setting parameters for adjusting infusion of the one or more anesthetic agents based on the one or more indices (e.g., in a closed-loop control). By this, a control with minimized latency can be obtained.
[0034] The control device may be configured to use a combined pharmacokinetic and pharmacodynamic model for modelling the pharmacokinetics and the pharmacodynamics of the one or more anesthetic agents in the patient’s body to compute the one or more setting parameters. This allows a precise adjustment of the setting parameters.
[0035] The control device may comprise an Al (Artificial Intelligence) model which is trained to select one of a plurality of models to compute the one or more setting parameters for adjusting infusion of the one or more anesthetic agents based on the one or more indices and / or on one or more patient characteristics. Hence, for example, depending on patient characteristics such as one or more of height, weight, body surface, age, gender, origin,MT25044
[0036] Page 7
[0037] color of skin and pathology, an optimized model and / or adjustment of the model can be obtained.
[0038] The one or more infusion pumps may be more than one infusion pump and comprise a first infusion pump for infusing a first one of the anesthetic agents to the patient in accordance with at least a first one of the setting parameters, and a second infusion pump for infusing a second one of the anesthetic agents to the patient in accordance with at least a second one of the setting parameters. A third infusion pump for infusing a third one of the anesthetic agents to the patient in accordance with at least a third one of the setting parameters may also be provided. By this, the system can provide all necessary anesthetic agents and also take into account potential mutual influences among the different anesthetic agents.
[0039] For example, the one or more indices comprise a first index relating to a first one of the effects (e.g., caused by the first anesthetic agent), and a second index relating to a second one of the effects (e.g., caused by the second anesthetic agent). This allows to provide reliable control of the anesthesia.
[0040] For example, the first anesthetic agent is a hypnotic agent and / or the second anesthetic agent is an analgesic agent. Therein, e.g., the first index relates to a hypnotic effect and / or the second index relates to an analgesic effect.
[0041] According to a specific example, the first index is an index of consciousness (also referred to as qCON) and / or the second index is an index of nociception (qNOX). By means of the indices the hypnotic effect (indicated by the index of consciousness, qCON) and the analgesic effect (indicated by the index of nociception, qNOX) are quantified, e.g., in a range between 0 and 100. For example, in E. W. Jensen et al., "Monitoring hypnotic effect and nociception with two EEG-derived indices, qNOX and qCON, during general anesthesia", Acta Anaesthesiologica Scandinavica, 2014; 58:933- 941 it is described how these indices may be computed. The index of consciousness, qCON, may for example be computed from clinical data using a model, for example as described in WO 2017 / 012622 A1. The index of nociception, qNOX, may also be computed using a model, in particular a fuzzy logic model (in particular a so-called ANFIS model) or a quadratic model, as for example described in WO 2017 / 012622 A1. The model, in particular, may be defined by a system of equations using a multiplicity of coefficients for computing said index of nociception from input data derived from an encephalography signal (EEG), wherein the coefficients in a training phase are derived using training data as input to the model. Once the training is completed the model is frozen and may be used,MT25044
[0042] Page 8
[0043] by the control device, during an actual anesthesia procedure to compute the index of nociception during the anesthesia procedure in real time to provide information with respect to nociception during GA. The indices, in one embodiment, are repeatedly computed, e.g. continuously with each new measurement of the one or more biological signals of the biosignal monitor, e.g. with each cardiac cycle. In particular, the different indices may be computed in real-time, such that real-time feedback based on the indices is obtained.
[0044] The control device may be configured to provide said first setting parameter to the first infusion pump for controlling operation of the first infusion pump for infusing the first anesthetic agent and / or to provide said second setting parameter to the second infusion pump for controlling operation of the second infusion pump for infusing the second anesthetic agent. This allows an automatic operation.
[0045] In one example, the screen is a part of the at least one infusion pump. That is, the screen may be arranged directly on this infusion pump which allows a specifically small setup that still provides the described functionality. The control device and / or the bio-signal monitor may also be part of the infusion pump.
[0046] According to another example, the screen is part of the control device. The control device may be communicatively coupled to the at least one infusion pump. The bio-signal monitor may be part of the control device or separate from the control device and communicatively coupled therewith. This allows to control a plurality of infusion pumps in a clear fashion.
[0047] For example, the bio-signal monitor and the control device and / or the control device and the one or more infusion pumps are, respectively, communicatively coupled compliant with the IEEE 11073 communication standard. This provides a real-time plug-and-play interoperability for medical devices and an efficient exchange of data, acquired at the point-of-care, in all care environments.
[0048] According to an example, the bio-signal monitor and the control device are communicatively coupled via a wired (e.g., serial) connection and / or via a wireless (e.g., Wi-Fi, e.g., according to IEEE 802.11) connection. For example, the bio-signal monitor and the control device are communicatively coupled via a wired connection and, additionally, via a wireless connection. Therein, the control device may be configured to test whether or not the wired connection is operational and to test whether or not the wireless connection is operational, and to start an infusion process for administering the one or more anesthetic agents to the patient only if both the wired connection and the wireless connection areMT25044
[0049] Page 9
[0050] operational. The same may be provided for the connections of the control system with the one or more infusion pumps.
[0051] According to an aspect, a method for providing advice for administering anesthetic agents to a patient is provided, the method comprises measuring, with a bio-signal monitor, at least one biological signal of the patient; computing, by a control device and / or the biosignal monitor and based on the at least one biological signal, one or more indices relating to one or more effects caused by one or more anesthetic agents; computing, by the control device, one or more setting parameters for adjusting one or more infusion pumps for infusing the one or more anesthetic agents to the patient; and concurrently displaying the one or more indices and the one or more setting parameters on a screen. The method may comprise further method steps corresponding to the procedures as described above with respect to the system.
[0052] The advantages and advantageous embodiments described above for the system equally apply also to the method, such that in that respect it shall be referred to the above.
[0053] The idea underlying the present disclosure shall subsequently be described in more detail by referring to the embodiments shown in the figures. Herein:
[0054] Fig. 1 shows a schematic view of a setup in an anesthesia procedure;
[0055] Fig. 2 shows a functional diagram of the setup of Fig. 1;
[0056] Fig. 3 shows a functional diagram of a model for modelling the distribution of a drug dosage in a patient’s body;
[0057] Fig. 4 shows a schematic drawing of a model for computing an index of consciousness (qCON);
[0058] Fig. 5 shows a schematic drawing of a model for computing an index of nociception (qNOX);
[0059] Fig. 6 shows a schematic drawing for a correction of a value for the index of nociception as output by the model;MT25044
[0060] Page 10
[0061] Fig. 7 shows a schematic drawing of an embodiment of a system for controlling an anesthesia procedure involving multiple anesthetic agents;
[0062] Fig. 8 shows a view of a computed index as a function of an effect-site concentration;
[0063] Fig. 9 shows different indices as a function of the effect-site concentrations of the different anesthetic agents independently associated with the different indices;
[0064] Fig. 10 shows the interaction functions H and I, with the effect-site concentrations or the index values as inputs, respectively; and
[0065] Fig. 11 illustrates a graphical user interface on a screen of the system of Fig. 1.
[0066] Subsequently, a system for administering one or more anesthetic agents to a patient and a method for providing advice for administering anesthetic agents to a patient in an anesthesia procedure which allow for a safe and reliable anesthesia procedure shall be described in certain embodiments. The embodiments described herein shall not be construed as limiting for the scope of the invention.
[0067] Like reference numerals are used throughout the figures as appropriate.
[0068] Fig. 1 shows a schematic drawing of a setup as it may be used for example in an anesthesia procedure for administering one or more anesthetic agents, in the following also referred to as anesthetic drug(s), such as propofol and / or remifentanil to a patient P. In this setup, a system 6 for administering one or more anesthetic agents D1, D2, D3 to a patient P is shown and applied. In this setup multiple devices of the system 6 are arranged on a rack 1 of the system 6 and are connected via different lines to the patient P.
[0069] Infusion pumps 31, 32, 33, in particular syringe pumps and / or volumetric pumps, are connected to the patient P and serve to intravenously inject, via lines 310, 320, 330, different anesthetic agents D1-D3 such as propofol, remifentanil and / or a muscle relaxant drug to the patient P in order to achieve a desired anesthetic effect. The lines 310, 320, 330 are for example connected to a single port providing access to the venous system of the patient P such that via the lines 310, 320, 330 the respective drugs can be injected into the patient’s venous system. The infusion pumps 31-33 are configured for infusing theMT25044
[0070] Page 11
[0071] anesthetic agents D1-D3 to the patient P in accordance with one or more setting parameters S1-S3 (see Fig. 2).
[0072] The rack 1 furthermore may hold a ventilation device 4 for providing an artificial respiration to the patient P while the patient P is under anesthesia. The ventilation device 4 is connected via a line 400 to a mouth piece 40 such that it is in connection with the respiratory system of the patient P.
[0073] The rack 1 also holds a bio-signal monitor 5 including, for example, an EEG monitor and an ECG monitor, the bio-signal monitors e.g. being adapted to sense biological signals of the patient P, e.g., signals by means of electrodes 50 attached to the patient’s P body for monitoring signals on the patient P during an anesthesia procedure. The electrodes 50 are electrically connected with the bio-signal monitor 5 via lines 500. An ECG sensor 53 is electrically connected with the bio-signal monitor 5 via lines 501.
[0074] In addition, a control device 2 is held by the rack 1. The control device 2 serves to control the infusion operation of one or multiple of the infusion pumps 31, 32, 33 during the anesthesia procedure such that infusion pumps 31 , 32, 33 inject anesthetic agents D1 , D2, D3 to the patient P in a controlled fashion to obtain a desired anesthetic effect. This shall be explained in more detail below.
[0075] The system 6 is configured to compute, based on the at least one biological signal, one or more indices relating to one or more effects caused by the one or more anesthetic agents D1, D2, D3.
[0076] The system 6 further comprises a screen 20. The control device 2 is configured to concurrently display the one or more setting parameters S1-S3 and the one or more indices on the screen 20. Here the screen 20 is a part of the control device 2. Alternatively, the screen 20 could be a part of one of the infusion pumps 31-33.
[0077] Fig. 2 shows a functional diagram of a control loop for controlling the infusion operation of the infusion pumps 31, 32, 33 during an anesthesia procedure. The control loop herein may be set up as a closed loop in which the operation of the infusion pumps 31, 32, 33 is automatically controlled without user interaction. Alternatively, the system is set up as an open-loop system in which at certain points of time, in particular prior to administering a drug dosage to a patient, a user interaction is required in order to manually confirm the operation.MT25044
[0078] Page 12
[0079] The system 6 may apply machine learning and Al to anticipate protocols and enhance the system's 6 adaptability. Using Al and machine learning, it is possible to further improve both an advisory and a closed-loop function by learning, through the increasing number of infusions and anesthetic parameters, to precisely adapt the TCI parameters depending on an extended set of patient characteristics: height, weight, body surface, age, gender, origin, color of skin, pathology and the like. With an extensive set of patient characteristics, the machine learning abilities improve the precision of the advised TCI model. Thus, the control device 2 may comprise an Al model trained to select one of a plurality of models to compute the one or more setting parameters S1-S3 for adjusting infusion of the one or more anesthetic agents D1-D3 based on the one or more indices and / or on one or more patient characteristics.
[0080] The control device 2 (which may also be denoted as “infusion manager”), is connected to the rack 1. The rack 1 may serve as a communication link to the infusion pumps 31 , 32, 33 also attached to the rack 1, the control device 2 and / or the other devices mounted on the rack 1. The control device 2 outputs control signals to control the operation of the infusion pumps 31, 32, 33, which according to the received control signals inject defined dosages of drugs to the patient P. For example, the control signals are indicative of flow rates and / or dose rates. Here, the control signals communicated to the infusion pumps 31, 32, 33 are (or are generated based on) setting parameters indicating a value to which the infusion pump shall be adjusted.
[0081] By means of the bio-signal monitor 5, e.g. comprising an EEG monitor, for example, an EEG reading of the patient P is taken. As such, the bio-signal monitor 5 may be configured to obtain, using the electrodes 50, biological signals in the form of EEG signals. Alternatively, or in addition, the bio-signal monitor 5 may be configured to obtain, using the an ECG sensor 53, biological signals in the form of ECG signals. The measured data obtained by the bio-signal monitor 5 is fed back to the control device 2, which correspondingly adjusts its control operation and outputs modified control signals (e.g., the setting parameters) to the infusion pumps 31 , 32, 33 to achieve a desired anesthetic effect.
[0082] As shown in Fig. 2, the control device 2 is configured to compute the setting parameters S1-S3 for adjusting infusion of the anesthetic agents D1-D3 based on the one or more indices in a closed-loop control. Here, the a first infusion pump 31 is provided for infusing a first one of the anesthetic agents D1 (e.g., propofol) to the patient P in accordance with a first one of the setting parameters S1, a second infusion pump 32 is provided for infusingMT25044
[0083] Page 13
[0084] a second one of the anesthetic agents D2 (e.g., remifentanil) to the patient P in accordance with a second one of the setting parameters S2, and a third infusion pump 33 is provided for infusing a third one of the anesthetic agents D3 to the patient P in accordance with a second one of the setting parameters S3 (e.g., a muscle relaxer). The first anesthetic agent D1 in the present example is a hypnotic agent and the second anesthetic agent D2 is an analgesic agent, wherein the first index relates to an hypnotic effect and the second index relates to an analgesic effect. Here, the first index is an index of consciousness qCON and the second index is an index of nociception qNOX, as will be described in further detail below.
[0085] The bio-signal monitor 5 and the control device 2 are communicatively coupled compliant with the IEEE 11073 communication standard. The control device 2 and the infusion pums 31-33 are communicatively coupled compliant with the IEEE 11073 communication standard.
[0086] In the present example, the bio-signal monitor 5 and the control device 2 are communicatively coupled via a wired connection 7 and, additionally, via a wireless connection 8. The control device 2 and the infusion pumps 31-33 are communicatively coupled via a wired connection 7 and, additionally, via a wireless connection 8. For this purpose, the bio-signal monitor 5, and control device 2 and the infusion pumps 31-33 comprise a wired interface 70 for the wired connection 7 and a wireless interface 80 for the wireless connection 8. Alternatively, only a wired or only a wireless connection may be provided.
[0087] This allows enhanced cybersecurity with Wi-Fi connectivity. In addition (or as an alternative) to serial connectivity, the system 6 includes Wi-Fi connectivity to meet modern cybersecurity standards. This dual connectivity approach ensures secure and reliable communication between the monitoring device(s) (e.g., bio-signal monitor 5) and the control system 2, protecting patient data and maintaining system integrity.
[0088] The system 6 supports the Service-oriented Device Connectivity (SDC) protocol, specifically the IEEE 11073 family of standards. The SDC protocol is designed to enable manufacturer-independent medical device-to-device interoperability, facilitating seamless communication between different medical devices and systems. The SDC standards family comprises three major parts. Core standards include the transport mechanism (ISO / IEEE 11073-20702), the domain information and service model (ISO / IEEE 11073-10207), and the architecture and binding definition (ISO / IEEE 11073-20701). The transport standard,MT25044
[0089] Page 14
[0090] known as Medical Devices Communication Profile for Web Services (MDPWS), enables foundational interoperability between medical devices, allowing them to exchange data safely in a distributed system and discover network participants dynamically.
[0091] In the present example the system 6 supports Participant Key Purposes (PKPs). These standards define technical, process, and documentation requirements to ensure safe, secure, and effective interconnection between medical devices from different manufacturers. PKPs include the Base PKP (ISO / IEEE 11073-10700), Metric PKP (ISO / IEEE 11073-10701), Alert PKP, and External Control PKP, each tailored to specific use cases.
[0092] In the present example the system 6 further supports Device Specializations (DevSpecs). These standards are specific to particular classes of medical devices, such as high-frequency equipment, endoscopic cameras, light sources, insufflators, and suction / irrigation pumps. DevSpecs ensure that devices within these categories can communicate effectively within the SDC framework.
[0093] By supporting the SDC protocol, the system 6 ensures compatibility with a wide range of monitoring devices and medical information systems, facilitating easier adoption and implementation in healthcare settings. This versatility allows the system to integrate seamlessly with existing hospital infrastructure, enhancing the overall efficiency and effectiveness of anesthesia delivery.
[0094] In the present example, the control device 2 is configured to check (e.g., perform a connectivity test such as a ping) if the wired connection 7 between the control device 2 and the bio-signal monitor 5 and the infusion pumps 31-33 is operational and to check (e.g., perform a connectivity test such as a ping) if the wireless connection 8 between the control device 2 and the bio-signal monitor 5 and the infusion pumps 31-33 is operational. The control device 2 is configured to start an infusion process for administering the one or more anesthetic agents D1-D3 to the patient P only if both the wired connection 7 and the wireless connection 8 are operational. If this is not the case, an alarm may be issued.
[0095] The control device 2 uses, to control the infusion operation of one or multiple infusion pumps 31, 32, 33, a pharmacokinetic-pharmacodynamic (PK / PD) model, which is a pharmacological model for modelling processes acting on a drug in the patient’s P body. Such processes include the infusion, the distribution, the biochemical metabolism, and the excretion of the drug in the patient’s P body (denoted as pharmacokinetics) as well as theMT25044
[0096] Page 15
[0097] effects of a drug in an organism (denoted as pharmacodynamics). Preferably, a physiological PK / PD model with N compartments is used for which the transfer rate coefficients have been experimentally measured beforehand (for example in a proband study) and are hence known. To simplify the PK / PD model not more than 4-5 compartments preferably are used.
[0098] A schematic functional drawing of the setup of such a PK / PD model is shown in Fig. 3. The PK / PD model logically divides the patient P into different compartments A1-A5, for example, a plasma compartment A1 corresponding to the patient’s P bloodstream, a lung compartment A2 corresponding to the patient’s P lung, a brain compartment A3 corresponding to the patient’s P brain and other compartments A4, A5 corresponding, for example, to muscular tissue or fat and connective tissue. The PK / PD model takes into account the volume Vmng, Vpiasma, Vbrain, Vj, Vj of the different compartments A1-A5 as well as transfer rate constants KPL, KLP, KBP, KPB, KIP; KPI, KJP, KPJ indicating the transfer rates between the plasma compartment A1 and the other compartments A2-A5, assuming that a drug dosage D by means on an infusion pump 33 is injected into the plasma compartment A1 and the plasma compartment A1 links the other compartments A2-A5 such that an exchange between the other compartments A2-A5 always takes place via the plasma compartment A1. KpO describes a constant rate for processes acting through metabolism or elimination that irreversibly removes the drug from the central compartment. The PK / PD model serves to predict the concentration CiUng, Cpiasma, Ce, Ci, Cj of the injected drug in the different compartments A1-A5 as a function of time.
[0099] During a GA procedure, carried out for example by using the control device 2 and a control in the sense of a target-controlled infusion (TCI), it generally is desired to be able to provide for an accurate assessment of an anesthetic state of a patient. For this, from information obtained during a GA procedure, e.g. biological signal, e.g., from EEG signals, obtained from the bio-signal monitor 5, indices shall be computed reflecting level of consciousness and a level of nociception of a patient during the anesthesia procedure.
[0100] This is schematically illustrated in Figs. 4 and 5. Namely, based on an EEG signal obtained during a GA procedure a first model M1 may be used to compute an index of consciousness qCON (Fig. 4), and a second model M2 may be used to compute an index of nociception qNOX (Fig. 5), as this is described for example in WO 2017 / 012622 A1. During a GA procedure, hence, the models M1, M2 are used to compute from an input EEG signal an index of consciousness qCON reflecting a level of consciousness, and an index of nociception qNOX reflecting a probability of response to noxious stimuli. Both indicesMT25044
[0101] Page 16
[0102] generally have values ranging from 0 to 100 (where higher values indicate an increased consciousness and nociception, respectively).
[0103] For computing the index of nociception qNOX, EEG data is fed to the model M2, and a value for the index of nociception qNOX is obtained as output from the model M2.
[0104] Herein, in addition to the qNOX definition described WO 2017 / 012622 A1 , an enhancement of the qNOX index, qNOXenhanced, may be employed by extending its formulation based on the EEG with several additional biosignals related to the nociception. Fig. 6 shows the scheme for the qNOXenhanced index, where a model M2enhanced is defined as a function of previously used EEG information, in M2 model for qNOX, and several nociceptive complementary parameters extracted such as the heart rate obtained from the ECG activity (e.g., using ECG sensor 53), the cardiac output obtained from both, ECG and impedance cardiography Zimp, and somatosensory evoked potential (SSEP) parameters embedded in the EEG activity that are time-locked to an external electrical stimulus.
[0105] The model M2 to compute the index of nociception may for example be a quadratic model or a fuzzy logic model, in particular an ANFIS model. Generally, the model M2 may be represented by a system of equations comprising a multiplicity of coefficients, which are suitably defined in an initial training phase by training the model M2 such that the model M2 reliably provides an output for the index of nociception when fed with input data derived from the EEG signal, as illustrated in Fig. 5.
[0106] Based on computed indices, operation of the infusion pumps 31-33 to administer different anesthetic agents to the patient P is performed. In particular, based on biological signals as measured by the bio-signal monitor 5 index values relating to different effects caused by the different anesthetic agents are computed, and based on the indices setting parameters are determined for controlling operation of the infusion pumps 31-33 to adjust the infusion operation for causing the different indices to converge towards predefined targets. As the control takes place based on indices relating to different effects, anesthesia is controlled with respect to specific effects, such that a reliable and safe procedure can be established.
[0107] Referring now to Fig. 7, in a general setup, the bio-signal monitor 5 may comprise an EEG monitor for measuring an electroencephalogram signal, an ECG monitor for measuring an electrocardiogram signal, an EMG monitor for measuring an electromyography signal, a hemodynamics monitor for measuring hemodynamic signals, such as the blood pressureMT25044
[0108] Page 17
[0109] or cardiac output, an impedance monitor for measuring bio-impedance signals, and / or a stimulation device for causing a stimulus on the patient P to measure a corresponding response. Further sensors may be present, such as motion sensors, for example, a piezoelectric sensor, for detecting motion for example in response to a stimulus applied to the patient P, a skin response sensor, a plethysmography sensor or the like.
[0110] In the embodiment shown in Fig. 7, the control device 2 comprises an extraction module 21 which serves to extract and compute indices based on bio-signals obtained from the bio-signal monitor 5. Alternatively, the extraction module 21 may be part of the bio-signal monitor 5.
[0111] Generally, two or more indices can be computed which relate to different effects caused by different anesthetic agents. In a setup in which for example two infusion devices 31-33 are used to administer two different anesthetic agents to the patient P (for example a hypnotic agent and an analgesic agent), two indices - which here are also referred to as index A and index B - may be computed, the first index A, for example, indicating an effect caused by the first anesthetic agent, for example, the hypnotic agent, and the second index B indicating an effect caused by the second anesthetic agent, for example, the analgesic agent.
[0112] The indices may be computed based on bio-signal measurements of the bio-signal monitor 5, for example, based on an EEG signal (with or without applying a stimulus by means of the stimulation device), an ECG signal, hemodynamics parameters, an impedance signal, and / or for example a plethysmography signal.
[0113] For example, index A relating to the effect of the first anesthetic agent, for example, a hypnotic agent, in the shown embodiment is computed entirely from the spontaneous EEG signal. As index A, reflecting the hypnosis depth, the qCON index is used, as described in WO 2017 / 012622 A1. In summary, the qCON index is defined as the output of a quadratic or ANFIS model whose parameters give the best fitting between several inputs, consisting in a set of EEG frequency bands and the percentage of quasi-isoelectric EEG periods for a given time, named Burst Suppression, to an output scalar that best correlates with the hypnotic drug (e.g. propofol) concentration Ce at the effect site. Posteriorly, the model output scalar is normalized to the range of 0 to 100 according to the index definition. The best fitting estimations of the model parameters are obtained from a dataset of EEG data and hypnotic drugs PKPD information collected from a large number of patients during GA during an initial training phase for training the model.MT25044
[0114] Page 18
[0115] This may be summarized by the following equation:
[0116] index A = M1(EEG) = qCON (EEG bands, EEG Burst Suppression)
[0117] Index B in the present example is defined as the index qNOX, as described in WO 2017 / 012622 A1, and is obtained as an output of a quadratic or ANFIS model whose parameters give the best fitting between several inputs, consisting in a set of EEG frequency bands and the percentage of quasi isoelectric EEG periods for a given time, named Burst Suppression, to an output scalar that best correlates with the analgesic drug effect-concentration, e.g. remifentanil Ce. Posteriorly, the model output scalar is normalized to the range of 0 to 100, according to the index definition. In this case, index B is obtained (only) from the EEG information. In such definition, the index B can be summarized mathematically as
[0118] index B = M2(EEG) = qNOX(EEG bands, EEG Burst Suppression)
[0119] In another embodiment, index B reflecting the level of analgesia is reformulated by extending the qNOX definition with extra parameters extracted from more biosignals and electrical stimulation, as this is illustrated in Fig. 6. The enhanced qNOX is a function of the EEG and (1) the evoked EEG activity (Somato-sensory evoked potential, SSEP) obtained by averaging the EEG activity at the time electrical stimuli are given, (2) the heart rate extracted from the ECG signal, (3) and the cardiac output obtained from the ECG and the impedance signal. The index B formulated in terms of its bio-signals is:
[0120] index B = M2 (EEG, SSEP, ECG, Zimp)
[0121] The electrical stimulation to elicit the SSEP denotes a response to controlled electrical stimuli between 1 to 50 mA (at 1 kQ load) using a predefined pulse pattern with pulse durations between 10 to 1000 ps and with a frequency in between 1 to 250 Hz, stimulating either the palpebral nerve or a hand nerve such as the radial nerve.
[0122] The features extracted from the EEG and used to feed the model are, in one embodiment, the same as the ones used according to the previous definition of qNOX, namely a set of frequency bands and a burst suppression measurement.MT25044
[0123] Page 19
[0124] The features extracted from the SSEP, which is obtained by a stimulus time-locked EEG average, are the amplitudes and latencies of the SSVEP components (N25, P60, N80), as well as a measure defined as the norm of the SSVEP derivate
[0125] i
[0126] N \ 2
[0127] ISSVEP = ^\sSVEP[i] - SSVEP[i + l])2I
[0128]
[0129] i = l /
[0130] The heart rate and the cardiac output are obtained by standard procedures using the ECG and the impedance amplitude and norm of the derivative.
[0131] Summarizing, the enhanced definition of index B, assigned to the analgesia effect, is as follows:
[0132] index B = M2 (EEG frequency bands, SSVEP peak amplitudes, SSVEP peak latencies, heart rate, cardiac output, Zimp amplitude, Zimp norm derivative)
[0133] If another, third anesthetic agent, for example, a muscular relaxant, is administered to the patient, a third index, index C, may be added to the multivariate controller to be controlled with the previous indexes A and B. This index relating to the (im-)mobility of the patient may be derived from a third model M3 whose inputs are the facial EMG obtained from energy of the EEG signal above 40 Hz and the norm of the averaged instant velocity and acceleration given by an accelerometer, placed on a muscle innervated by the electrical stimuli used to elicit the SSVEP used in the enhanced index B definition. Thus, the definition of index C requires an electrical stimulation.
[0134] The index C in terms of its input signals can be formulated as:
[0135] Index C = M3(EEG, accelerometers)
[0136] or specifically as
[0137] index C = M3 (energy EEG band >40 Hz, norm(v), norm(a))
[0138] The model parameters are adjusted to an index in a range between 0 to 100, giving the best fit to the probability of movement observed in a large dataset of patients under GA with muscular relaxants. The energy EEG band > 40 Hz modulates accelerometer responses not related with the electrical stimulus-response.MT25044
[0139] Page 20
[0140] The indices as derived by the extraction module 21 are fed to a controller module 23, together with an output from a modelling module 22 in which the pharmacokinetic and pharmacodynamic behavior of the different anesthetic agents is modelled within the different compartments of the patient P. The controller module 23 then computes setting parameters, which are fed towards the infusion devices 31-33 to adapt the operation of the infusion devices 31-33, in particular a dose rate by which the different anesthetic agents are administered to the patient P.
[0141] The system 6 as depicted in Fig. 7 herein may be operated in a closed-loop configuration or in advisory configuration. For this, a switch module 24 is provided, by means of which a user, in particular an anesthesia practitioner, may choose between the different configurations. In the closed-loop configuration, the setting parameters as computed by the controller module 23 are directly fed to the infusion devices 31-33. In the open-loop configuration, in turn, the system 6 functions as an advisory system in which the setting parameters are determined by the controller module 23 and are displayed to the user for confirmation, wherein the setting parameters are fed to the infusion devices 31-33 only upon confirmation by the user, wherein the user may also adapt the setting parameters.
[0142] Referring now to Fig. 8, generally, an index depends on the effect-site concentration Ce of a particular anesthetic agent. For example, if propofol is used, as hypnotic agent, the corresponding index A representing the level of consciousness, qCON, may generally have a value in between 0 to 100, wherein 100 indicates maximum consciousness and low values of the index indicate a reduced level of consciousness (see Fig. 8 on the left). Similarly, if remifentanil is used as an analgesic agent, the corresponding index B, in this case, the qNOX or the qNOXenhanced, is scaled to the range between 0 to 100 and indicates the response to noxious stimuli (see Fig. 8 on the right). From Fig. 8 it can be seen that both indices are functions of their corresponding effect-site concentrations. The functions shown, index=0(Ce), are obtained fitting the so-called Hill equation from an extensive dataset of thousands of patients undergoing GA under propofol and remifentanil.
[0143] Referring now to Fig. 9, different anesthetic agents may exhibit a different effect-site concentration, and indices relating to the different anesthetic agents and indicating an effect associated with the particular anesthetic agent exhibit a different dependency on a respective effect-site concentration. Similarly, combined dose-response, Fig. 11, and its equivalent index-response bivariate functions, and their parameterization are obtained by fitting the Minto's interaction model or other sigmoidal-wise bivariate function on extensiveMT25044
[0144] Page 21
[0145] datasets. The dose-response interaction parameters for different drug combinations are reported in the literature for different datasets (Boullion 2004, Kern 2004). The indexresponse function I is obtained by substituting the doses by the indexes in the Hill interaction parametric model using the independent Hill dose-response equations.
[0146] Generally, the specific effect of a particular anesthetic agent as indicated by the index relating to the particular anesthetic agent may be modelled by a Hill equation. The Hill equation herein is adapted for the different anesthetic agents, such that each anesthetic agent causes a different specific effect (index A, index B index C in Fig. 9) based on a particular effect-site concentration Ce of that particular anesthetic agent.
[0147] In addition, if multiple anesthetic agents are administered to the patient P in combination, the different anesthetic agents generally interact. This can be modelled using the anaestetics interaction model (H), such as the parametric Minto's interaction model as described in WO 2023 / 041552 A1.
[0148] This is illustrated in Fig. 10, showing the 2D surface interaction model (H) as a function of the effect-site concentrations of drug A and drug B at some probability response values. This is an example of a synergistic drug interaction model, where the contour levels of H have a hyperbola shape, wherein the same effect is achieved with lower drug concentrations when both drugs are combined.
[0149] If parameter p>0, there is a synergistic interaction between drug A and drug B. Changes in the concentration of drug A, potentiating effect A, will have some effects in index B, potentiating also its corresponding effect, and vice versa. Particularly, drugs like the hypnotic propofol and the analgesic remifentanil have a synergistic effect. If p<0, both drugs have an infra-activity or antagonist behaviour. Changes in the concentration of drug A, potentiating effect A, will have some effects in index B by reducing effect B, and vice versa.
[0150] The anaesthetics interaction models, which are reported in the literature for different drug combinations as parametric surfaces such as the Minto’s interaction model, serve to enhance the quality of the control actions that performing the control actions on each drug separately, facilitating faster times to reach the indexes targets as well as stability.MT25044
[0151] Page 22
[0152] The Hill equations for the different anesthetic agents as well as the interaction models are adjusted in advance from extensive datasets, such that the Hill equations and the interaction models are predefined in the system.
[0153] A target is defined for the different effects caused by the different anesthetic agents, the target being expressed by for example a desired range of the index associated with each anesthetic agent. Hence, a desired range for index A is defined, and in addition a desired range for index B is defined, the control operation of the control device 2 being implemented to adjust operation of the infusion devices 31-33 to cause the indices to converge to their predefined target regions. For instance, the hypnotic effect under propofol and its associated effect-index quantified via the qCON index can be set to a moderate hypnosis, a range between 60-80, while the analgesic effect induced with remifentanil and quantified with the enhanced version of the qNOX can be set e.g. in a surgical context to a depth analgesia protection, corresponding to a range between 30-40. The target region behaves as the tolerance deviation accepted in the controller from the center point target. The controller module 23 is adapted to compute the setting parameters for adapting the operation of the infusion devices 31-33 based on the indices as computed by the extraction module 21.
[0154] In particular, target values in the shape of target regions for the different indices are fed to the controller module 23, in addition to actual, momentary values for the indices, for example index A and index B (e.g. qCON and qNOX) and both effect site concentrations given by the PKPD models.
[0155] Example details of ANFIS models and quadratic equation models are provided in WO 2023 / 041552 A1.
[0156] Fig. 11 illustrates the screen 20 with a graphical user interface (GUI) displayed thereon. Within the GUI, the screen 20 concurrently displays at least some of the setting parameters S1-S3 (here setting parameters S1 and S2 are displayed). Each one of the setting parameters S1, S2 is displayed together with the corresponding indices as time series on the screen 20 and overlaid in a single diagram (here one diagram for the first anesthetic agent D1 and one for the second anesthetic agent D2).
[0157] The screen 20 may be arranged separately of other components of the control device 2, or, e.g., be mounted in the same housing. On the center of the screen 20 (in this example; in other examples this may be arranged differently), a function “Ce Ref” is provided andMT25044
[0158] Page 23
[0159] can be activated as soon as the patient P is unconscious. Doing this, the user can memorize the given concentration of the TCI model in a memory of the control device 2 and / or anticipate the patient’s consciousness during the whole anesthetic operation.
[0160] The proposed system 6 incorporates the indices such as qCON and qNOX which provide precise and real-time monitoring of the patient's depth of anesthesia and pain response, allowing for more accurate adjustments to the anesthesia delivery. This integration ensures that the anesthesia is tailored to the patient's needs, enhancing both safety and efficacy.
[0161] The proposed system 6 provides connectivity versatility with SDC Protocol. The system 6 supports the SDC protocol (IEEE 11073), which provides compatibility with a wide range of monitoring devices. This versatility allows the system 6 to integrate seamlessly with existing hospital infrastructure, facilitating easier adoption and implementation.
[0162] The proposed system 6 may use artificial intelligence and machine learning to anticipate protocols and enhance system 6 adaptability. By analyzing historical data and real-time inputs, the system 6 can predict the patient's P needs and adjust the anesthesia delivery accordingly. This proactive approach improves patient P outcomes and reduces the risk of complications.
[0163] The system 6 connects the bio-signal monitor 5 to the control device 2, allowing for comprehensive monitoring and reporting on the Therapy Manager qCON and qNOX indices in front of TCI curves (anesthetics and analgesics). This integration provides a holistic view of the patient's anesthesia status, enabling more informed decision-making by healthcare professionals.
[0164] The system 6 may also use the Rugloop algorithm, which adjusts TCI (Target-Controlled Infusion) based on the patient's monitored parameters. In advisory mode, the system provides recommendations to the anesthesiologist, who can then accept or adjust the suggested settings. In closed-loop mode, the system 6 automatically adjusts the anesthesia delivery based on real-time monitoring, ensuring optimal anesthesia depth and patient safety. The Rugloop program was written by Tom De Smet and Michel Struys it is described in WO 2005 / 072792 A1.
[0165] The system 6 may perform a plausibility check with the EEG signals or other biological signals (and / or the index calculated thereon) and, e.g., the amount of infused corresponding drug. If these values do not match, an alarm may be issued. This providesMT25044
[0166] Page 24
[0167] an additional level of security. As such, the control device 2 may calculate an expected index based on the amount of infused drug and compare the expected index with the calculated index. Depending on the comparison, an alarm may be issued if the two values differ by more than a predefined threshold. In that manner, the control system 2 may also be configured to detect if a sensor (e.g., the electrodes 50) is operational or shall be replaced (e.g., when the compared values show a characteristic deviation). In the latter case the control system 2 issues a warning indicating that a replacement is necessary.
[0168] A method for providing advice for administering anesthetic agents D1-D3 to a patient P comprises:
[0169] measuring, with a bio-signal monitors, at least one biological signal of the patient P;
[0170] computing, by a control device 2 and / or the bio-signal monitor 5 and based on the at least one biological signal, one or more indices relating to one or more effects caused by one or more anesthetic agents D1-D3;
[0171] computing, by the control device 2, one or more setting parameters S1-S3 for adjusting one or more infusion pumps 31-33 for infusing the one or more anesthetic agents D1-D3 to the patient P; and
[0172] concurrently displaying the one or more indices and the one or more setting parameters S1-S3 on a screen 20.
[0173] The method may use the system 6 described above.
[0174] The control device comprises a processor 25 and memory 26 storing instructions that, when executed by the processor, cause the processor to perform the method described above.MT25044
[0175] Page 25
[0176] List of Reference Numerals
[0177] 1 Rack
[0178] 2 Control device
[0179] 20 Screen
[0180] 21 Extraction module
[0181] 22 Modelling module
[0182] 23 Controller module
[0183] 24 Switch module
[0184] 25 Processor
[0185] 26 Memory
[0186] 31, 32, 33 Infusion device
[0187] 310, 320, 330 Line
[0188] 4 Ventilation device
[0189] 40 Mouth piece
[0190] 400 Line
[0191] 5 Bio-signal monitor 50 Electrodes
[0192] 500, 501 Line
[0193] 53 ECG sensor
[0194] 6 System
[0195] 7 Wired connection
[0196] 70 Wired interface
[0197] 8 Wireless connection 80 Wireless interface A1-A5 Compartments
[0198] D Drug dosage
[0199] D1, D2, D3 Anesthetic agent M1, M2 Model
[0200] P Patient
[0201] qCON Index of consciousness qNOX Index of nociception S1, S2, S3 Setting parameter
Claims
MT25044Page 26Claims:
1. A system (6) for administering one or more anesthetic agents (D1-D3) to a patient (P), the system (6) comprising:a bio-signal monitor (5) for measuring at least one biological signal of the patient (P), wherein the system (6) is configured to compute, based on the at least one biological signal, one or more indices relating to one or more effects caused by the one or more anesthetic agents (D1-D3);one or more infusion pumps (31-33) for infusing one or more anesthetic agents (D1-D3) to the patient (P) in accordance with one or more setting parameters (S1-S3);a screen (20); anda control device (2) configured to concurrently display the one or more setting parameters (S1-S3) and the one or more indices on the screen (20).
2. The system (6) according to claim 1, characterized in that the control device (2) is configured to concurrently display the one or more setting parameters (S1-S3) and the one or more indices as time series on the screen (20), wherein at least one of the one or more setting parameters (S1-S3) and at least one of the one or more indices are overlaid in a single diagram.
3. The system (6) according to claim 1 or 2, characterized in that the control device (2) is configured to compute the one or more setting parameters (S1-S3) for adjusting infusion of the one or more anesthetic agents (D1-D3) based on the one or more indices in a closed-loop control.
4. The system (6) according to claim 3, characterized in that the control device (2) is configured to use a pharmacokinetic-pharmacodynamic model for modelling the pharmacokinetics and the pharmacodynamics of the one or more anesthetic agents (D1-D3) in the patient’s (P) body to compute the one or more setting parameters (S1- S3).
5. The system (6) according to claim 3 or 4, characterized in that the control device (2) comprises an Al model trained to select one of a plurality of models to compute the one or more setting parameters (S1-S3) for adjusting infusion of the one or moreMT25044Page 27anesthetic agents (D1-D3) based on the one or more indices and / or on one or more patient characteristics.
6. The system (6) according to one of the preceding claims, characterized in that the one or more infusion pumps (31-33) comprise a first infusion pump (31) for infusing a first one of the anesthetic agents (D1) to the patient (P) in accordance with a first one of the setting parameters (S1), and a second infusion pump (32) for infusing a second one of the anesthetic agents (D2) to the patient (P) in accordance with a second one of the setting parameters (S2).
7. The system (6) according to claim 6, characterized in that the one or more indices comprise a first index relating to a first one of the effects caused by the first anesthetic agent (D1), and a second index relating to a second one of the effects caused by the second anesthetic agent (D2).
8. The system (6) according to claim 7, characterized in that the first anesthetic agent (D1) is a hypnotic agent and the second anesthetic agent (D2) is an analgesic agent, wherein the first index relates to an hypnotic effect and the second index relates to an analgesic effect.
9. The system (6) according to claim 7 or 8, characterized in that the first index is an index of consciousness (qCON) and the second index is an index of nociception (qNOX).
10. The system (6) according to one of claims 7 to 9, characterized in that the control device (2) is configured to provide said first setting parameter (S1) to the first infusion pump (31) for controlling operation of the first infusion pump (31) for infusing the first anesthetic agent (D1) in accordance with the first index and to provide said second setting parameter (S2) to the second infusion pump (32) for controlling operation of the second infusion pump (32) for infusing the second anesthetic agent (D2) in accordance with the second index.MT25044Page 2811. The system (6) according to one of the preceding claims, characterized in that the screen (20) is part of the at least one infusion pump (31-33).
12. The system (6) according to one of claims 1 to 10, characterized in that the screen (20) is part of the control device (2), wherein the control device (2) is communicatively coupled to the at least one infusion pump (31-33).
13. The system (6) according to one of the preceding claims, characterized in that the bio-signal monitor (5) and the control device (2) are communicatively coupled compliant with the IEEE 11073 communication standard.
14. The system (6) according to one of the preceding claims, characterized in that the bio-signal monitor (5) and the control device (2) are communicatively coupled via a wired connection (7) and via a wireless connection (8), wherein the control device (2) is configured to test if the wired connection (7) is operational and to test if the wireless connection (8) is operational, and to start an infusion process for administering the one or more anesthetic agents (D1-D3) to the patient (P) only if both the wired connection (7) and the wireless connection (8) are operational.
15. A method for providing advice for administering anesthetic agents (D1-D3) to a patient (P), the method comprising:measuring, with a bio-signal monitor (5), at least one biological signal of the patient (P);computing, by a control device (2) and / or the bio-signal monitor (5) and based on the at least one biological signal, one or more indices relating to one or more effects caused by one or more anesthetic agents (D1-D3);computing, by the control device (2), one or more setting parameters (S1-S3) for adjusting one or more infusion pumps (31-33) for infusing the one or more anesthetic agents (D1-D3) to the patient (P); andconcurrently displaying the one or more indices and the one or more setting parameters (S1-S3) on a screen (20).
